Compare SNPS & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNPS | BSX |
|---|---|---|
| Founded | 1986 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0B | 93.4B |
| IPO Year | 1994 | 2010 |
| Metric | SNPS | BSX |
|---|---|---|
| Price | $392.65 | $61.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $540.71 | $103.38 |
| AVG Volume (30 Days) | 1.4M | ★ 14.3M |
| Earning Date | 05-27-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.20 |
| EPS | 0.34 | ★ 1.94 |
| Revenue | $5,081,542,000.00 | ★ $9,076,000,000.00 |
| Revenue This Year | $39.19 | $11.91 |
| Revenue Next Year | $10.73 | $10.26 |
| P/E Ratio | $1,189.62 | ★ $31.60 |
| Revenue Growth | ★ 20.87 | 12.49 |
| 52 Week Low | $376.18 | $60.59 |
| 52 Week High | $651.65 | $109.50 |
| Indicator | SNPS | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 29.13 |
| Support Level | $377.84 | N/A |
| Resistance Level | $447.88 | $76.77 |
| Average True Range (ATR) | 13.90 | 1.76 |
| MACD | 0.74 | -0.13 |
| Stochastic Oscillator | 20.43 | 10.23 |
Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.